Tandem Diabetes Care (Nasdaq:TNDM) announced positive study data for its artificial pancreas using Control-IQ technology. The study demonstrated improved blood sugar control in children ages 2-6 with type 1 diabetes. It evaluated an artificial pancreas using the Tandem t:slim x2 insulin pump with Control-IQ technology. Results were published in the New England Journal of Medicine. […]
Clinical Trials
Study supports RenovoRx drug-device combo for treating pancreatic cancer
RenovoRx (Nasdaq:RNXT) today announced promising interim data for its RenovoGem drug-device combination for treating pancreatic cancer. The Tiger-Pac clinical trial investigates RenovoGem as a potential treatment option in locally advanced pancreatic cancer (LAPC). Interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem. RenovoGem utilizes the […]
Study backs Medtronic next-gen MiniMed 780G insulin pump for type 1 diabetes
Medtronic (NYSE:MDT) announced today that one-year data backs the use of its next-generation MiniMed 780G automated insulin pump. The ADAPT study compared MiniMed 780 G against multiple daily injections of insulin with an intermittently scanned CGM. ADAPT, which included 82 subjects, marks the first multi-national, randomized controlled study comparing these methods. The study evaluated adults […]
Fractyl Health ‘encouraged’ by results from diabetes reversal study
Fractyl Health announced today that six-month data from a study of its diabetes reversal tech demonstrated improvements in glucose control. Interim data came from the human clinical experience in Fractyl’s Revita-T2Di long-term, open-label cohort. Revita, a procedure that remodels the duodenal lining via hydrothermal ablation, has FDA breakthrough device designation. The FDA approved an investigational […]
Study backs digital diabetes program from Vida Health
Vida Health announced that a study of its digital health diabetes management program demonstrated improvements in multiple metrics. San Francisco-based Vida Health published an article in JMIR Formative Research. Results from 1,128 participants demonstrated dramatic improvements in glycemic control. It also highlighted an important relationship between the improved management of depression and diabetes. Participants enrolled in […]
Canadian university set for Phase 2 human trials of inhaled COVID-19 vaccine
Researchers at McMaster University in Canada announced that they received $8.2 million from the Canadian Institutes of Health Research (CIHR). Fiona Smaill picked up $8.2 million to advance an inhaled COVID-19 vaccine through to Phase 2 human trials. The trials will evaluate the safety and immunogenicity of the next-generation vaccine delivered by inhaled aerosol. Her […]
Oramed may discontinue oral insulin activity for type 2 diabetes after trial misses endpoints
Oramed Pharmaceuticals (Nasdaq:ORMP) announced that top-line Phase 3 trial results for its oral insulin candidate missed its endpoints. The Phase 3, randomized, double-blind, placebo-controlled trial compared the efficacy of ORMD-0801 to placebo. It evaluated patients with type 2 diabetes at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control. Those patients were […]
This AI-based smartphone app helps diabetes patients manage blood sugar
Oregon Health & Science University (OHSU) combined AI and diabetes experts to develop a smartphone app to help manage blood sugar levels. OHSU biomedical engineer Peter Jacobs and OHSU endocrinologist Dr. Leah Wilson lead this project. They plan to organize a randomized clinical trial to evaluate an enhanced app used in concert with diabetes education […]
MedAlliance picks up FDA IDE nod for drug-eluting balloon
MedAlliance announced today that its novel sirolimus-eluting balloon received conditional FDA investigational device exemption (IDE). Geneva, Switzerland-based MedAlliance can now initiate its pivotal clinical trial for the treatment of coronary de novo lesions. MedAlliance received its first IDE for Selution SLR in below-the-knee indications in May 2022. It picked up a second IDE in August. […]
Sustained Therapeutics advances novel drug delivery platform
Sustained Therapeutics announced that it received regulatory approval in Canada to begin a Phase II trial of its novel pain medication. Vancouver, BC-based Sustained Therapeutics develops a long-lasting non-opioid pain medication. Its trial evaluates a sustained-release platform technology to aid in chronic pain treatment. The company said in a news release that it designed the […]
